A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting

BACKGROUND Oral corticosteroids (OCS) are commonly administered in patients with severe persistent allergic asthma. Despite their efficacy, they are associated with a wide variety of adverse events. The eXpeRience registry was set up to investigate real-world outcomes among patients receiving omalizumab for the treatment of uncontrolled allergic asthma. Here, we present the effect of omalizumab...

متن کامل

Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting

Background Patients with severe allergic asthma (SAA) are often inadequately controlled despite available treatments including high-dose inhaled corticosteroids and longacting b2-agonists. Use of oral corticosteroids (OCS) in SAA patients may not achieve full asthma control, and leads to significant long-term side effects. Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (...

متن کامل

Effectiveness of Omalizumab in Reducing Corticosteroid Burden in Patients With Moderate to Severe Persistent Allergic Asthma

STUDY POPULATION. Patients (N 1071) were aged 12 to 75 years with moderate-to-severe persistent allergic asthma that was inadequately controlled with ICSs. Eight percent of the patients were aged 12 to 18 years. All patients had confirmed allergic asthma, an immunoglobulin E (IgE) level between 30 and 700 IU/mL, and a baseline forced expiratory volume in 1 second (FEV1) between 40% and 80%. Dat...

متن کامل

Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.

OBJECTIVE Approved by the FDA in 2003, omalizumab is the first recombinant humanized monoclonal anti-immunoglobulin E antibody developed for the treatment of allergic asthma. Due to the heterogeneity of asthma symptoms, investigation of the efficacy of omalizumab in patients outside controlled trials is particularly important. The purpose of the current study was to evaluate the efficacy of oma...

متن کامل

Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma.

BACKGROUND Asthma guidelines advocate maintaining asthma control while minimizing corticosteroid exposure. OBJECTIVE To assess the reduction in corticosteroid burden during long-term treatment and the corresponding impact of this reduction on asthma control, lung function, and inflammation in patients with moderate to severe allergic asthma. METHODS We conducted a pooled analysis (N = 1,071...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: British Journal of Clinical Pharmacology

سال: 2017

ISSN: 0306-5251

DOI: 10.1111/bcp.13453